Results 241 to 250 of about 89,572 (287)

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer. [PDF]

Oncologist
Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig MB, Maxwell KN, Schoen MW.   +11 more
europepmc   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Docetaxel.

British journal of hospital medicine, 1997
Paclitaxel was the first taxoid to become available. It was found to be an active anticancer agent but with significant toxicity. Docetaxel is a semisynthetic taxoid and the next of a fast-expanding class of drugs. Studies suggest that docetaxel may be more effective and less toxic than paclitaxel.
Leahy, M, Howell, A; id_orcid 0000-0002-6233-719X   +1 more
core   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Docetaxel

Drugs, 2012
Katherine A Lyseng‑Williamson, Caroline Fenton, Katherine A Lyseng-Williamson   +2 more
exaly   +6 more sources

Docetaxel

Drugs, 2007
Docetaxel is a taxane analogue that inhibits microtubule disassembly and, in cultured gastric cancer cells, induces apoptosis-associated binding activity of the transcription factor activating protein-1, and activates the proapoptotic genes BCL2L1 and BAX.
Emma D, Deeks, Lesley J, Scott
openaire   +3 more sources

Docetaxel extravasation

Supportive Care in Cancer, 2001
We report on an accidental extravasation of docetaxel given intravenously as chemotherapy in a cancer patient. The extravasate was immediately diluted subcutaneously with saline, in addition to which hypothermia (ice-packs) was implemented and topical dimethylsulfoxide (DMSO) was applied three times every 45 min.
P, Berghammer, R, Pöhnl, M, Baur, C, Dittrich   +3 more
openaire   +2 more sources

DOCEtaxel

Reactions Weekly, 2022
Michelle C. Simpson, Eric G. Schaefer
  +4 more sources

Docetaxel

Reactions Weekly, 2015
  +7 more sources